Effect of Recombinant Human Growth Hormone Add on Therapy on Acute Stroke Outcome.
- Author:
Ga Heon JIN
1
;
Jun Beom LEE
Author Information
- Publication Type:Original Article
- Keywords: Recombinant Human Growth Hormone; Cytidine Diphosphate Choline; Modified Barthel Index; Rankin Scale
- MeSH: Brain; Cytidine Diphosphate Choline; Human Growth Hormone*; Humans*; Injections, Subcutaneous; Insulin-Like Growth Factor I; Stroke*
- From:Brain & Neurorehabilitation 2018;11(1):e4-
- CountryRepublic of Korea
- Language:English
- Abstract: Recombinant human growth hormone (rhGH) administration stimulate the secretion of the brain insulin-like growth factor-1 (IGF-1) concentration and IGF-1 is a pleiotropic neurotropic peptide to exert beneficial effect for the injured brain tissues. Citicoline (cytidine-59-diphosphocholine; CDP-choline) is well known to improve neurological outcome in acute stroke. This study aimed to evaluate whether rhGH can potentiate citicoline effect on functional recovery in acute stroke patient. Thirty patients were enrolled. Ten patients were treated with rhGH subcutaneous injection for 6 months on top of citicoline for 6 weeks (GH6 group), and 10 patients for 3 months (GH3 group) with 6 weeks of citicoline treatment as well, and final 10 patients only with citicoline (control group). Functional outcome was determined by Korean modified Barthel Index (K-MBI) and modified Rankin Scale (mRS) at baseline and 6 months after treatment. Seven and 4 patients withdrew from GH6 and GH3 group, respectively. Final 3 patients in GH6 group, 6 patients in GH3 group and 10 patients in control group were analyzed. The K-MBI, and mRS scores from all 3 groups increased in 6 months compared to baseline in intra-group comparison. In inter-group comparison, however, GH6 but not GH3 showed statistically significant improvement compared to control. Administration of rhGH for 6 months on top of 6-week citicoline treatment resulted in further improvement in K-MBI and mRS in acute stroke patients. Further studies in increasing injection dose or injection period is needed.
